Case Report: Amiodarone-induced multi-organ toxicity

被引:2
作者
Yan, Jingrui [1 ]
Xu, Yuanyuan [2 ]
Zhu, Qiang [1 ]
机构
[1] Shandong First Med Univ, Shandong Prov Hosp, Dept Gastroenterol, Jinan, Shandong, Peoples R China
[2] Shandong First Med Univ, Dept Med Imaging, Affiliated Hosp 2, Tai An, Shandong, Peoples R China
来源
FRONTIERS IN CARDIOVASCULAR MEDICINE | 2024年 / 11卷
关键词
amiodarone; atrial fibrillation; adverse reaction; thyroid; lung; liver; case report; ATRIAL-FIBRILLATION; MANAGEMENT; LUNG;
D O I
10.3389/fcvm.2024.1401049
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Amiodarone is a class III antiarrhythmic drug that is commonly used in the clinic to treat ventricular arrhythmias and atrial fibrillation. We present a case report of the adverse effects of amiodarone and review its characteristics.Case report A 73-year-old Asian female with a history of paroxysmal atrial fibrillation managed with amiodarone, well-controlled hypertension, and no substance abuse presented with gastrointestinal distress and dizziness, without chest pain or palpitations. Despite normal annual check-ups, she developed abnormal liver and thyroid function tests, and imaging revealed lung and liver changes suggestive of amiodarone toxicity. Discontinuation of amiodarone for sotalol led to symptom improvement and normalization of thyroid and liver functions, with imaging indicating recovery from interstitial fibrosis and reduced liver density.Discussion Amiodarone, a widely used for treating ventricular and atrial arrhythmias, and with significant benefits in improving patient survival in cases of ventricular fibrillation. However, its long-term use is associated with serious adverse effects, including thyroid dysfunction, liver injury, and pulmonary toxicity, necessitating careful monitoring and management. Despite its efficacy, the need for research on early detection and management of amiodarone's side effects is crucial, highlighting the importance of regular monitoring and possibly adjusting therapy to mitigate these risks.
引用
收藏
页数:8
相关论文
共 32 条
  • [1] Incidence of thyroid dysfunction following initiation of amiodarone treatment in patients with and without heart failure: a nationwide cohort study
    Ali, Sam Aiyad
    Ersboll, Mads
    Vinding, Naja Emborg
    Butt, Jawad Haider
    Rorth, Rasmus
    Selmer, Christian
    Westergaard, Lucas Malta
    Mogensen, Ulrik Madvig
    Weeke, Peter E.
    Jons, Christian
    Gustafsson, Finn
    Fosbol, Emil
    Kober, Lars
    Kristensen, Soren Lund
    [J]. EUROPACE, 2023, 25 (02): : 291 - 299
  • [2] Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: A meta-analysis
    Chevalier, P
    Durand-Dubief, A
    Burri, H
    Cucherat, M
    Kirkorian, G
    Touboul, P
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (02) : 255 - 262
  • [3] Effects of amiodarone therapy on thyroid function
    Cohen-Lehman, Janna
    Dahl, Peter
    Danzi, Sara
    Klein, Irwin
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2010, 6 (01) : 34 - 41
  • [4] de Denus S, 2003, AM J HEALTH-SYST PH, V60, P1791, DOI 10.1093/ajhp/60.17.1791
  • [5] CLINICAL-FEATURES OF AMIODARONE-INDUCED PULMONARY TOXICITY
    DUSMAN, RE
    STANTON, MS
    MILES, WM
    KLEIN, LS
    ZIPES, DP
    FINEBERG, NS
    HEGER, JJ
    [J]. CIRCULATION, 1990, 82 (01) : 51 - 59
  • [6] Amiodarone: A Comprehensive Guide for Clinicians
    Hamilton Sr, David
    Nandkeolyar, Shuktika
    Lan, Howard
    Desai, Pooja
    Evans, Jonathan
    Hauschild, Christopher
    Choksi, Dimpa
    Abudayyeh, Islam
    Contractor, Tahmeed
    Hilliard, Anthony
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2020, 20 (06) : 549 - 558
  • [7] 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
    Hindricks, Gerhard
    Potpara, Tatjana
    Dagres, Nikolaos
    Arbelo, Elena
    Bax, Jeroen J.
    Blomstroem-Lundqvist, Carina
    Boriani, Giuseppe
    Castella, Manuel
    Dan, Gheorghe-Andrei
    Dilaveris, Polychronis E.
    Fauchier, Laurent
    Filippatos, Gerasimos
    Kalman, Jonathan M.
    La Meir, Mark
    Lane, Deirdre A.
    Lebeau, Jean-Pierre
    Lettino, Maddalena
    Lip, Gregory Y. H.
    Pinto, Fausto J.
    Thomas, G. Neil
    Valgimigli, Marco
    Van Gelder, Isabelle C.
    Van Putte, Bart P.
    Watkins, Caroline L.
    [J]. EUROPEAN HEART JOURNAL, 2021, 42 (05) : 373 - 498
  • [8] Flow-cytometric analysis on adverse effects of polysorbate 80 in rat thymocytes
    Hirama, S
    Tatsuishi, T
    Iwase, K
    Nakao, H
    Umebayashi, C
    Nishizaki, Y
    Kobayashi, M
    Ishida, S
    Okano, Y
    Oyama, Y
    [J]. TOXICOLOGY, 2004, 199 (2-3) : 137 - 143
  • [9] AMIODARONE PHARMACOKINETICS
    HOLT, DW
    TUCKER, GT
    JACKSON, PR
    STOREY, GCA
    [J]. AMERICAN HEART JOURNAL, 1983, 106 (04) : 840 - 847
  • [10] Intravenous amiodarone in intensive care - Time for a reappraisal?
    Hughes, M
    Binning, A
    [J]. INTENSIVE CARE MEDICINE, 2000, 26 (12) : 1730 - 1739